Th17 Inflammatory Pathway Therapeutics Markets, 2022

News provided by

Jul 26, 2019, 10:45 ET

DUBLIN, July 26, 2019 /PRNewswire/ -- The "Th17 Inflammatory Pathway Therapeutics Report" report has been added to ResearchAndMarkets.com's offering.

Immune-mediated inflammatory diseases (IMIDs) is a term that encompasses a number of common, chronic and complex disorders, characterized by a dysregulation of the normal immune response which leads to inflammation in target organs and, usually, systemic effects as well.

Examples include type 1 diabetes (T1D), Crohn's disease (CD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS) and psoriasis. This report examines the therapeutic products and strategies that are being employed to improve outcomes by modulating the intracellular production of inflammatory mediators.

What You Will Learn

What are the immune factors in the Th17 helper cell pathway that are responsible for immune-mediated inflammatory Autoimmune Diseases?
What are the inflammatory-mediated ligands, receptors, signalling proteins and transcription factors that represent druggable targets in the Th17 helper cell?
What are the major factors driving the high level of development activity in immune-mediated inflammatory diseases?
What is the size of the market today, who are the market share leaders, and what will the market share be in 2022?
What are the significant economic, technology, and regulatory factors affecting the market for immune therapeutics

Key Topics Covered:

Executive Summary
The Th17 Pathway

Th17 Inflammatory Pathway Cascade Targets

Interleukin 6 (IL-6)
Approved Drugs
Development-stage Drugs
Interleukin IL-6R
Approved Drugs
Development-stage Drugs

Janus Kinase/Tyrosine Kinase Inhibitors

Approved Drugs
Development-stage Drugs
Signalling Proteins

Signal Transducer and Activator of Transcription (STAT)

Interleukin-21 (IL-21)
Interleukin-21R (IL-21R)
Interleukin-23 (IL-23)
Approved Drugs
Development-stage Drugs
Interleukin-23R (IL-23R)
Interleukin-17A (IL-17A)
Approved Drugs
Interleukin-17C (IL-17C)
Development-stage Drugs
Interleukin 17A/17F
Development-stage Drugs
Interleukin-17RA (IL-17RA)
Approved Drugs

Transforming Growth Factor- RI/RII (TGF- RI/RII)

Development-stage Drugs
Retinoic acid-related orphan receptor (RORyt)
Development-stage Drugs
Interleukin 17
Development-stage Drugs
Interleukin-22 (IL-22)
Market Status
Market Size
Competitive Landscape

Th17 Pathway Mediated Inflammatory Diseases

Addressable Market
Competitive Landscape
Profiles of Market Participants

For more information about this report visit https://www.researchandmarkets.com/r/2bckw7

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets